Eisai Of Japan Obtains Approval To Launch Hepatitis Drug Clevudine In Philippines
This article was originally published in PharmAsia News
Executive Summary
Japanese drug maker Eisai obtained March 13 approval to market the chronic hepatitis B drug clevudine in the Philippines from the Bureau of Food and Drugs. Eisai's Philippine subsidiary, Hi-Eisai Pharmaceutical, will launch the drug under the name Levovir. There are an estimated 8 million patients infected with the hepatitis B virus in the Philippines. Eisai has also applied for regulatory approval to market clevudine in India, Indonesia, Malaysia and Thailand and plans to file for approval to market the drug in Singapore and Vietnam. (Click here for more - Japanese language